JPRN-UMIN000035235招募中2 期
ab-Paclitaxel plus trastuzumab and pertuzumab followed by EC as a neoadjuvant chemotherapy for HER2-positive operable breast cancer - PerSeUS-BC04
Gifu University Graduate School of Medicine Department of Surgical Oncology0 个研究点目标入组 30 人开始时间: 2018年12月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Inflammatory and/or bilateral breast cancer 2)Duplicated/sunchromus/metachromus cancer(DFS less than 5y) 3)Severe complication (cardiovascular, lung, liver disease, homorragic ulcer etc.) 4)febrile, susupicious for infection 5)Interstitial pneumonia or pulmonary fibrosis by chest-X/CT 6)Active systhemic infevtion (HBV, HCV, HIV etc.) 7)Uncontrollable pheripheral pneuropathy due to DM, V-12 deficiency etc. 8)Severe allergy to drug 9)Pregnancy, Lactation 10)Uncontrollable mental disease 11)Not suitable for this study judged by physician/Surgeon
研究者
相似试验
招募中
2 期
ab-Paclitaxel plus trastuzumab and pertuzumab as a neoadjuvant chemotherapy for low-risk HER2-positive breast cancerBreast CancerJPRN-UMIN000051060Gifu University Graduate School of Medicine Breast Surgery35
已完成
不适用
A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer.advanced gastric cancerJPRN-UMIN000006403Toyama Prefectural Central Hospital30
已完成
1 期
Phase1/2 study of nab-Paclitaxel + trastuzumab therapy in 2nd line treatment for HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.HER2-positive gastric cancerJPRN-UMIN000014873Kyoto Prefectural University of Medicine, Gatroenterology and Hepatology23
招募中
1 期
Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive.advanced or recurrent HER2-positive gastric cancerJPRN-UMIN000008623The Cancer Institute Hospital of JFCR36
进行中（未招募）
1 期
Avelumab + Paclitaxel/ Ramucirumab als Zweitlinientherapie beim gastro-ösophagealen Adenokarzinom: eine Phase-II-Studie der AIO - RAP-Studiemetastatic gastro-oesophageal cancerMedDRA version: 21.1Level: LLTClassification code 10066354Term: Adenocarcinoma of the gastroesophageal junctionSystem Organ Class: 100000004864EUCTR2018-002938-20-DECharite - Universitätsmedizin Berlin59